OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-12-31-accounts

THE UROLOGY FOUNDATION

TRUSTEES’ REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1

The Urology Foundation Annual Report & Accounts 2024

CONTENTS

STATEMENT FROM THE CHAIR AND CHIEF EXECUTIVE ......................................................... 3 OBJECTIVES AND ACTIVITIES ..................................................................................... 5 A YEAR IN VIEW..................................................................................................... 7 ACHIEVEMENTS AND PERFORMANCE IN 2024 ................................................................... 7 FINANCIAL REVIEW ............................................................................................... 23 STRUCTURE, GOVERNANCE & MANAGEMENT ................................................................. 28 REFERENCE AND ADMINISTRATIVE DETAILS ................................................................... 30 TRUSTEES’ & DIRECTORS’ RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS ..... 31 REPORT OF THE INDEPENDENT AUDITORS .................................................................... 32 STATEMENT OF FINANCIAL ACTIVITIES ........................................................................ 35 BALANCE SHEET .................................................................................................. 37 CASHFLOW STATEMENT ......................................................................................... 38 NOTES TO THE FINANCIAL STATEMENTS ...................................................................... 39

2

The Urology Foundation Annual Report & Accounts 2024

STATEMENT FROM THE CHAIR AND CHIEF EXECUTIVE

People diagnosed and living with urological cancers and conditions seek information, support and interventions that enable them to get the help, support and care they need to navigate the challenges of everyday life. The Urology Foundation is the only charity in the UK representing the entire spectrum of urology health and disease through our investment in world class research, training and education programmes for our urology community and allied healthcare professionals, campaigns to raise public awareness and commitment to driving policy change.

Building on the many achievements of 2023 we set out an ambitious and exciting programme for 2024. Thanks to the support and commitment of our stakeholders, including the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and our generous supporters, we have achieved so much. Highlights include:

3

The Urology Foundation Annual Report & Accounts 2024

Our success and achievements would not have been possible were it not for the efforts and commitment of so many people and the generosity of our wonderful supporters. Sincere thanks to all those who have supported us and contributed to the many achievements of 2024.

Mary Garthwaite, Chair

Rebecca Porta, CEO

4

The Urology Foundation Annual Report & Accounts 2024

OBJECTIVES AND ACTIVITIES

The Urology Foundation’s objectives are to:

“Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work.”

OUR VISION AND MISSION

We see a world where people will not die early from urological cancers and diseases, and where people with problems of the bladder, kidneys, prostate and male reproductive organs can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research, training, and education, campaigning, policy change, support and information, ensuring patients receive the best possible treatment and care and fewer lives are devastated.

OUR AIMS

The Urology Foundation is committed to reducing the burden caused by urological diseases. We work with researchers, urology and healthcare professionals to improve the diagnosis, treatment and management of urological disease and the nation’s urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

OUR VALUES

In undertaking our remit, we are:

WHAT WE DO

We seek to improve patient treatment and care through investing in world class research, education and training programmes, raising public awareness and driving change in policy. We fund research that increases our understanding of urological cancers and conditions, and that can bring about change in urology practice and guidelines for the benefit of patients and their families. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement

5

The Urology Foundation Annual Report & Accounts 2024

in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Awareness campaigns such as Urology Awareness Month in September bring urological cancers and conditions to the public eye, breaking the stigma and taboos associated with these diseases and conditions and encouraging people to seek an early diagnosis where they may be concerned about potential early warning signs and symptoms.

PUBLIC BENEFIT

The Trustees have taken The Charity Commission’s general guidance on public benefit into consideration in preparing their statements on public benefit contained within this annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-forprofit organisations to:

In addition, the charity provides information on urological cancers and conditions, raises awareness, campaigns and drives policy change.

GRANTS POLICY

The Foundation advertises its programmes and awards on its website, through its professional e- newsletter and networks. Applications for research are assessed by an independent Scientific and Education Committee (SEC) and Review Panel.

The charity is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial partner. Research studies funded through our NIHR approved funding streams are automatically eligible for consideration for NIHR Research Delivery Network (RDN) support subject to meeting the standard study eligibility criteria.

6

The Urology Foundation Annual Report & Accounts 2024

A YEAR IN VIEW

ACHIEVEMENTS AND PERFORMANCE IN 2024

OUR RESEARCH STRATEGY

The Urology Foundation (TUF) was delighted to launch a new Research Strategy, ‘Improving urology health: transforming lives through research. Research Strategy 2024-2028’ in July. The Strategy was developed in consultation with a wide range of stakeholders – urology healthcare professionals and researchers, patients and their families, policy makers and wider stakeholders - to understand priorities for TUF’s work moving forward. Some clear messages came through regarding disease priority areas and types of research and programmes we should fund, and it was gratifying to see that there was significant agreement among our stakeholders on these areas. The Research Strategy is built on four key pillars, each with clearly defined objectives:

The strategy is a bold, exciting, and ambitious vision. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders – the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters - our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change. At the heart of our strategy are patients and their families: involving and working with people affected by urological disease, embedding patient integration and engagement in research, and ensuring they have a “voice” in shaping future research agendas and priority areas.

OUR RESEARCH PROGRAMMES

Innovation & Research Awards

Our Innovation & Research Awards fund projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods.

We are pleased to report that eight awards totalling £499,532 were made in 2024 (in 2023 there were eight awards totalling £431,592). The eight projects were:

Multi-modal cfDNA surveillance following radical treatment for high-risk penile cancer Penile cancer is a rare but impactful disease often diagnosed late due to limited awareness, leading to severe consequences for patients and their families. Current treatments are invasive and can leave lasting side effects, with no reliable blood tests or scans to monitor progress effectively. This project aims to revolutionise penile cancer care by developing a non-invasive blood test using "liquid biomarkers," which are DNA fragments shed from tumours or the associated HPV virus.

The study, conducted at The Christie NHS Foundation Trust and the Cancer Research UK National Biomarker Centre, will analyse blood samples from 100 patients to detect these biomarkers. Success could mean earlier cancer detection, fewer surgeries, and better-tailored treatments, ultimately improving patient outcomes and reducing the burden on healthcare systems. This innovative

7

The Urology Foundation Annual Report & Accounts 2024

approach promises to enhance the quality of life for men with penile cancer by allowing remote monitoring and more precise treatment strategies.

- Malignant ureteric obstruction in prostate cancer: a national population based study Over 50,000 men are diagnosed with prostate cancer every year across England and Wales. Half of these men have advanced cancer that spreads outside of the prostate and may cause complications to the whole body. Cancerous prostate growth may obstruct the urinary system and more specifically the tubes that drain the kidney, this is called malignant ureteric obstruction and may lead to pain, infections, kidney damage, and death. The true numbers and consequences of malignant ureteric obstruction in prostate cancer are unknown. Currently, patients and clinicians are not well-informed on who is at most risk and how best to manage this problem.

This study will use population-based data to answer key questions surrounding malignant ureteric obstruction including which patients are at the highest risk of developing the problem, the best treatments to prevent the problem and the best method of managing the problem.

Characterising lymphatics in bladders affected by posterior urethral valves using advanced 3D imaging techniques

Posterior Urethral Valves (PUV) are a condition that only occurs in boys and is characterised by abnormal tiny flaps of tissues at the level of the urethra, the final channel that carries urine outside the body. These tissue membranes, so called PUV, can partly block normal urine flow, which can cause problems at the level of the bladder and kidneys. In fact, around half of the boys with PUV will end up having major kidney issues requiring dialysis or transplantation. A big reason for the kidney problems is that PUV block the passage of urine, the bladder fills too much and stops functioning properly over time, which causes the kidney to become swollen and damaged.

Preserving bladder health and function is paramount to prevent kidney problems in boys with this disease. This project will determine how bladder lymphatics are laid out in health and how these change in PUV. They will conduct 3D imaging experiments utilising human bladder samples from boys undergoing surgery for PUV and will also apply this technique to a new mouse model that their lab has developed, which mimics the human disease.

Ward Admission of Symptomatic Haematuria: an Observational mUlticentre sTudy (WASHOUT) Around 25,000 patients require emergency admission for blood in the urine each year in the UK. Patients often stay in hospital for several days, experiencing painful retention of urine, and may need blood transfusions or emergency interventions. Clinicians are not sure what the best management strategy is because there are no guidelines or evidence on how to best manage these patients. The care provided to patients in hospital may vary with the hospital they are in, the consultant on call, and other considerations such as the time of the week.

The WASHOUT study aims to observe how these patients are managed in hospital and assess important outcomes such as length of hospital stay, timing of operations, cost of scans and operations, and the frequency of re-admissions. Study findings may show which types of management have better outcomes. Findings from WASHOUT will also help clinicians to produce guideline documents and carry out clinical trials in this field.

- Gene therapy for early onset genetic bladder disease

This project will focus on an inherited condition that affects nerves in the bladder and can lead to kidney infections and even failure in children. The researchers have developed a gene therapy strategy to treat mice with this condition, and excitingly, were able to completely restore the function of the bladder nerves, showing the gene therapy is successful. To bring this therapy closer to the clinic the study will address two key questions:

  1. What is the oldest we can effectively deliver the treatment? To inform whether the therapy is likely to be successful in babies, children, or adults.

8

The Urology Foundation Annual Report & Accounts 2024

2. Is therapy effective and safe in the longer term?

A nested case-control study of BK and JC polyomaviruses as risk factors for urothelial carcinoma in Malmö Diet and Cancer Study (MDCS) serum samples.

The DNA of nearly all bladder cancers carry the fingerprints of damage caused by some of the cell’s own proteins called ‘APOBECs’. The APOBECs are enzymes which defend against infections, like BK virus, by damaging viral DNA. During BK virus infection, we have evidence that APOBECs can cause collateral damage to a cell’s own DNA, potentially leading to the development of bladder cancer.

This research will look at blood samples from the Swedish Malmö Diet and Cancer Study for antibody proteins targeting BK virus. An abundance of antibodies shows that a person’s immune system has recently fought BK virus. It will investigate if individuals with more BK antibodies in their blood were at increased risk of developing bladder cancer. If BK virus is shown to be a risk factor, this research could lead to many cases of bladder cancer being seen as preventable through the development of new antiviral drugs and vaccinations.

We are grateful to the Charles Reynolds Foundation for their funding towards the above six research projects.

- Investigating combination BH3 mimetics and identifying accompanying biomarkers as a new therapeutic strategy for prostate cancer

Prostate cancers often have increased levels of certain proteins of a family called ‘BCL-2 family’. The increase in these proteins can prevent cancer therapies from successfully eliminating prostate cancer cells. A new class of drugs, called BH3-mimetics, can improve cancer cell elimination, and counteract disease recurrence by blocking BCL-2 proteins. The use of these drugs has been shown to be effective in cancers of the blood but have not been explored in depth in prostate cancer. This project will generate data on how BH3-mimetics can be used to eradicate prostate cancer cells. The ability of therapies to effectively eliminate cancer cells will be influenced by the neighbourhood in which the cancer is growing. Thus, the research aims to better understand the changes that the prostate cancer neighbourhood experiences when using BH3-mimetics and help identify which patients will benefit most from these new treatments.

The role of PSMA related metabolites in the progression and treatment of Prostate Cancer Radiotherapy is often used in conjunction with hormone therapy to treat prostate cancer. There is a set regimen which is the same for each patient. Some men may respond better or worse to radiation and the biology behind this is an active area of research. Other than PSA blood test monitoring over the longer term (months to years) there is no short term, rapid, measure of response to radiation in the prostate. Such a measure could be used to further adjust radiation for each patient, downscaling treatment to avoid side effects. This project aims to develop a convenient rapid test to monitor radiation treatment response by measuring the metabolites in the urine within existing radiation treatment appointments.

We are grateful to the John Black Charitable Foundation for their funding of the above two prostate cancer projects.

Smaller Research Projects Fund

The Smaller Research Projects Fund is focused on improving treatment and care and supports projects up to the value of £10,000. The Fund is aimed at projects that can be delivered quickly (within two years) and are focused on supporting vital research that seeks to improve the quality of clinical services and patient treatments and care.

We are pleased to report that six awards totalling £53,500 were made in 2024 (in 2023 there were five awards totalling £50,000). The projects were:

9

The Urology Foundation Annual Report & Accounts 2024

We are grateful to the charity Penguins Against Cancer for their co-funding of the above bladder cancer project.

Our work in Urinary Tract Infections (UTIs)

Urinary Tract Infections (UTIs) are a major health concern affecting millions globally each year. These infections not only cause pain and discomfort but all too often affect overall well-being, with many experiencing either repeated or chronic infections that significantly impact on quality of life. UTIs can also lead to more serious complications such as kidney infections, sepsis, and kidney damage if left untreated. UTIs are the second most common reason for prescribed antibiotics and have been identified by the World Health Organisation (WHO) as a significant factor in antimicrobial resistance. In 2024, The Champniss Foundation generously pledged £250,000 to be used specifically for a new research programme into UTIs.

TUF convened two Roundtable Meetings involving clinicians and researchers working in UTIs, and people with lived experience of recurrent and chronic UTIs. These meetings were to help indentify :

The discussion on pertinent research questions and the current challenges in UTI research was focused on five areas:

The information from these Roundtables was used to scope the call for UTI research applications. The call was opened in September and awards are expected to be made in Spring 2025, following a robust review process with an initial Expressions of Interest round before progress to the full application round.

10

The Urology Foundation Annual Report & Accounts 2024

In addition to the above work, TUF was invited to become a partner on a James Lind Alliance, UTI Priority Setting Partnership with Antibiotic Research UK and Bladder Health UK. The TUF Director of Research sits as a charity partner member of the steering group, which includes representation from healthcare professionals working in UTIs, experts in antimicrobial infection and patients with lived experience. This piece of work will last approximately 18 months and is expected to prioritise the most important areas of research to patients and researchers.

The TUF Trials Unit

Following our successful partnership with The Centre for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen to create the TUF Trials Unit (TTU), we renewed our relationship for a further three years in 2024, at funding of £60,000 per annum. During the year, the TTU managed to lever in just under £1 million of funding (£953,000) in support of the following research:

This was in addition to the previous £6.1 million funding from the National Institute of Health and Social Care (NIHR) to conduct three large-scale, multi-centre trials across the United Kingdom:

CHaRT has committed to increasing capacity and proactive engagement with unit by committing more named methodologists and statisticians to support the TTU. Their work includes:

TUF GRANTS MANAGEMENT SYSTEM

During 2024 TUF implemented a bespoke grants management system, TUF Grant Tracker. The system has proven to be a comprehensive way of recording applications, recipients, reviewers, timelines, deliverable outputs, payments, sponsors, and liabilities for each grant. Through using the TUF Grant Tracker for over a year, monitoring the status of the grants has been significantly streamlined. The Tracker flags ‘late outputs’ which helps to ensure we receive reports from grant awardees and can therefore make timely payments. It is possible to generate records of grant awards across the four nations, regions, disease areas etc. using the system. The Tracker also provides historical data for

11

The Urology Foundation Annual Report & Accounts 2024

comparison. Both aspects have been utilised when the team needs to compile information on grants, and the Tracker enables this to be done quickly and efficiently. It has also enabled efficient collection and recall of information on research results and impact. The charity currently has over 80 active grants and awards.

PATIENT AND PUBLIC INVOLVEMENT AND ENGAGEMENT (PPIE) PROGRAMME

In 2023 the charity launched its Patient and Public Involvement and Engagement (PPIE) programme. The PPIE Programme brings together researchers, people affected by urological cancers and conditions, their carers and the public, to help drive research forward. It is an opportunity to get involved in helping to plan, design, manage, evaluate, and communicate about research and leads to research that is relevant, appropriate, and better-designed with clearer outcomes, and is therefore well placed to have an impact. The key aims of the PPIE Programme are:

In 2024 we established the programme’s workflows and developed the associated documents required to ensure a smooth process for patients and members of the public joining the programme. We also secured our place providing PPIE support for two new research projects at the Freeman Hospital and University of Nottingham. 2025 will see the charity carrying out targeted recruitment drives for these projects and meetings for patients and public to input into the projects as well as developing resources for professionals to explain the support we can offer.

In 2024 Rosie Cockroft was appointed as Grants Executive and PPIE Lead to support the growing programmes and grants portfolio and the development of our PPIE Programme. The Programme is overseen by a PPIE Development Board - members include Imran Ahmed (Professor of Urological Oncology / Urological & Robotic Surgeon at the University of Glasgow), Hannah Warren (Research Fellow, Urology Registrar), Helen Lake (Urology Nurse), Lesley Booth (specialist in public engagement within medical research) and Susannah La-Touche (Urology Consultant at St George's University Hospital).

IMPROVING KNOWLEDGE AND SKILLS THROUGH EDUCATION AND TRAINING

FELLOWSHIPS

Fellowships enhance urological training, education, knowledge transfer, and collaboration. They are an important stage in professional and career development, and in building and supporting outstanding surgical leaders in their field. Fellows go to study a particular specialism or technique, so they can provide that service in their own hospitals on return. Through the acquisition of new skills and knowledge, Fellows make an important contribution to the advancement of science and practice thereby ensuring better outcomes for patients. TUF offers a variety of different Fellowship opportunities.

David Thompson Fellowship

The David Thompson Fellowships are worth up to £35,000 per Fellow. The grant supports attending a centre or centres of excellence for up to one year to enable candidates to gain invaluable experience and skills in urology care and best practice, and to make contributions to research in their area of

The Urology Foundation Annual Report & Accounts 2024

specialty. Successful candidates will act as ambassadors promoting best practice and sharing knowledge amongst their own team, hospital, and wider urology community.

In 2024 we were again delighted to receive a number of strong applications. Thanks to the generosity of the Thompson Family Charitable Trust, which sponsors the Fellowships, we were able to make the following awards:

We are grateful to the Thompson Family Charitable Trust for enabling these Fellowships.

Malcolm Coptcoat Travelling Fellowship

The Malcolm Coptcoat Fellowship, worth £5,000, enables trainees to travel to international centres of excellence for a period of four to six weeks to gain invaluable experience and skills in urology care and best practice. In 2024 the Fellowship was awarded to Miss Elizabeth Day, a post-CCT Fellow based at UCL, London. Miss Day chose to visit two European Centres – the Rijnstate Hospital in Arnhem, The Netherlands, and the Martini Klinik in Hamburg, Germany. At both centres she had the opportunity to observe surgery and understand the variations in techniques to prostate and bladder cancer surgery and the rationale for these, in order to expand her understanding of the different approaches. She was also able to gain an insight into the non-technical aspects such as organisational and systems cultures, including ways of assessing continual improvement of care.

TUF/Urolink Fellowships

The TUF/Urolink Fellowships, worth up to £1,500, are open to those senior level trainees who have completed their FRCS (Urol), enabling them to experience working in Low or Middle Income (LMIC) countries. The Fellowships help develop urological services in these countries, as well as enabling the cross-fertilisation of knowledge and skills, benefiting the professional development of both the Fellow and those working in healthcare systems where the annual per capita income is less than $1,135 a year. In 2024 four awards were made to:

Visits will take place in 2025 across a number of hospitals in Ghana, Malawi and Tanzania.

13

The Urology Foundation Annual Report & Accounts 2024

SUPPORT FOR UROLOGY TRAINEES AND UROLOGY NURSES

Keith Yeates Medal/Ralph Shackman Prize

The Medal and Prize are conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2024 there were three winners of the medal and the Shackman travelling fellowship worth £2,000.

Nurse Education and Training

TUF is committed to ensuring urology nurses and allied healthcare professionals have opportunities to enhance their skills and practice and increase their specialist knowledge. We also believe career advancement goals should be supported, and that further education may open up specialist urology nursing positions in oncology or stones, or roles such as advanced nurse practitioner and urology nurse clinician. We received significant take up of TUF’s Nurse Bursary awards in 2024, worth up to £5,000 each. Successful applicants were:

In addition, we funded a further nine nurses with travel grants worth up to £500 each to attend study days and nursing conferences in the UK and Europe.

We are grateful to the Charles Reynolds Foundation for their ongoing support of these awards and opportunities for urology nurses.

Regional Trainee Awards and Best of the Regions

In 2024, continuing our support for urology trainees, TUF provided £500 prizes to the Best Trainee Presentation or Paper given at a regional meeting of the British Association of Urological Surgeons (BAUS). There are 16 regions throughout the British Isles and Republic of Ireland. The winners of each region were then invited to present their papers at the annual BAUS Conference, at which the overall ‘Best of the Regions’ would be selected and win a further £500 prize. The overall winner in 2024 was Sorcha O’Meara, a trainee from the Republic of Ireland, for her paper on Holmium Yag Laser Injury in Human Ureter .

14

The Urology Foundation Annual Report & Accounts 2024

Support for Robotic Surgery Training

Once again, TUF provided support to two of our TUF Centres of Robotic Training, to run cadaveric courses for trainees. The courses are designed for surgeons, urologists, and multi-disciplinary teams to gain system knowledge and develop a working understanding of the robot and learn technical skills useful in the operating theatre. The Freeman Hospital in Newcastle, and Guy’s Hospital in London were each given £10,000 to provide the training courses over 2 days. The courses mixed lectures and videos with hands-on robotic surgery practice.

Supporting Advanced Consultant Training

TUF funded the Advanced Urology Simulation Boot Camp course with a £12,000 grant. The course is aimed at senior urology trainees and new consultants, supporting the transition to a consultant role, and provides training in often overlooked areas such as dealing with stress, effective leadership, and the day-to-day challenges of consultant practice. The course was extremely well attended and received excellent feedback.

Support for Travel, Conferences and Educational Programmes

During the year, a number of small grants were made to urologists and allied healthcare professionals to travel to, or attend, training courses, or conferences.

TRAINING AND EDUCATION

As part of our commitment to training and supporting our urology community and those with an interest in urological cancers and conditions, the charity delivered training sessions and attended conferences. Highlights include:

During the year TUF CEO was invited to join the Advisory Board of Knowlex. Knowlex provide a wide range of educational resources and activities for the healthcare community and commissioning organisations including conferences, panel debates, webinars, and an excellent online resource centre. The Advisory Board provides advice and insight to Knowlex and its work.

15

The Urology Foundation Annual Report & Accounts 2024

SUPPORTING PATIENTS AND THEIR FAMILIES

LAUNCH OF THE UTI INFORMATION SERVICE

Urinary tract infections (UTIs) are the second most common kind of infection (after chest infections). The National Institute for Health Research (NIHR 2016) report that UTIs are among the most common types of infections within excess of 92 million people affected worldwide. Around 50% of all women develop a UTI at some stage. An estimated one million women in the UK live with chronic UTIs and experience debilitating, consistent pain.

UTIs are a significant cause of mortality, especially amongst the elderly population, with UTI related symptoms accounting for between 1-3% of all primary care consultations and being the main reason for 13.7% of community antibiotic prescriptions. There is a higher-than-expected number of patients being admitted to hospital with a UTI or a UTI associated condition compared to trips, falls etc. UTIs can cause severe confusion which develops quickly over a couple of days, especially in older people.

There was a considerable body of evidence which showed people affected by UTIs would welcome information and support in understanding and managing the condition. With the generous support of The Champniss Charitable Trust and The Champniss Foundation this year saw the launch of a dedicated Nurse led UTI Information Service.

The aim of the Information Service is to provide up-to-date, quality information, support and a “listening ear” to anyone affected by or interested in UTIs including patients, their families, carers, healthcare professionals including those with an interest in UTIs, care home staff, GPs, and pharmacists. The Service responds to the needs of patients and carers for information, advice and support in understanding and managing the condition via a freephone Helpline, email and UTI Hub featuring a range of resources. The Service is open two days per week to support anyone with a concern about UTIs. This includes chronic and recurrent UTIs, symptoms and risk factors, UTIs in men, treatment options, when to request a referral to a urologist and the latest research. The dedicated email service launched on the 20 March 2024 - nurse@theurologufoundation.org and the freephone Helpline launched on the 30 July 20204 - 0808 801 1108.

The following resources were developed during the year:

Information and training for health and social care professionals is a key part of the Service. Alongside developing dedicated resources, the Service was promoted at conferences, training sessions, and UTI clinics and via industry partners, pharmacy networks, and the media.

The Service is led by Helen Lake. A Urology Specialist Nurse with over 35 years of experience in both the NHS and the private sector, Helen is exceptionally qualified to deliver this new Service. Her expertise spans a wide range of urology conditions, including Bladder Dysfunction, Urinary Tract Infections, Bladder Pain, Prostate conditions (Prostatitis, Benign Prostatic Enlargement), Prostate

16

The Urology Foundation Annual Report & Accounts 2024

Cancer, other Urology Cancers, Erectile Dysfunction, and Male Infertility. Her career highlights include Ward Sister and a Clinical Nurse Specialist in Urology Stoma and Continence, running NurseLed Clinics, Lead Urology Specialist Nurse and Clinical Educator at B. Braun Medical Limited, Honorary Urology Specialist Nurse at The Newcastle upon Tyne Hospitals NHS Foundation Trust, and Specialist Urology Nurse at Convatec. Before joining the charity Helen was Director of Men’s Health at Peppy Health. She is a former Trustee for the British Association of Urology Nurses (BAUN) and Nurse Advisor for The Urostomy Association. She has contributed significantly to the field through published peerreviewed articles and as a contributing author to the RCN Guidelines on Male Infertility. Helen is affiliated with the Royal College of Nursing.

FEEDBACK FROM USERS OF THE UTI INFORMATION SERVICE

‘Information given and resources on the website brilliant’

‘Thank you for being kind and welcoming’

‘Thank you for kindly taking the time to ring me back. It was very helpful and left me feeling more positive than I have for a long time’.

‘I am so glad to hear that there is planned research to look at future testing for UTIs that are not always picked up by current testing’

‘Thank you so much for listening, believe me it helps. I myself have worked in the NHS for many years and it is good to see that there are people striving to help people with these conditions, and that research is ongoing’

Thanks for everything u have done (young enquirer)

Thank you so much for speaking with me, and providing a helpful summary below. After sharing the information with my GP, I have been referred to a specialist UTI clinic!

‘I am so glad I have found you’

IMPROVING PUBLIC AWARENESS OF UROLOGICAL CANCERS AND CONDITIONS

TUF is committed to improving public awareness of urological cancers and conditions, to promoting research progress and highlighting research developments, to commenting on topical issues and sharing patient experience.

OUR WORK IN WESTMINSTER

In February, we attended a Parliamentary Roundtable ‘Driving service innovation: preparing for the future of prostate cancer care’ . The Roundtable was an opportunity to examine how current and future challenges facing prostate cancer services can be addressed through innovation in service delivery and new models of care. The event was supported by Astellas

In April we hosted a Parliamentary Reception together with the Urology Trade Association (UTA) titled: ‘ Putting patients first: promoting best practice in the continence sector’ . This was our third Reception with the UTA and over 80 stakeholders attended the event including policy makers, medical technology companies, researchers, clinicians, specialist nurses, funders, patients and charities. Over 14 Parliamentarians were in attendance. The reception was an opportunity to discuss continence issues and to identify what best practice in continence care should look like.

17

The Urology Foundation Annual Report & Accounts 2024

In November we attended Prostate Cancer Research’s Parliamentary reception, ‘Prostate Cancer Research: Cost Benefit Analysis Report’ at the House of Commons. The event saw the launch of a new report ‘ Socio-economic Impact of Prostate Cancer Screening ’ and attracted excellent crossparty support.

In December we attended a Parliamentary drop-in event organised by Johnson & Johnson and hosted by Sadik Al-Hassan MP. TUF and Prostate Cancer Research were given the opportunity to raise key issues on cancer care with Members of Parliament. Seventeen MPs attended the event.

CAMPAIGNS

Throughout the year we took part and supported a number of campaigns including World Cancer Day, Bladder Cancer Awareness Month, Prostate Cancer Awareness Month, “We See You” campaign, World Kidney Day, Testicular Cancer Month and World Continence Week. Highlights include:

Urology Awareness Month

September is Urology Awareness Month, an annual campaign which brings together our urology community – researchers, urologists, nurses and allied healthcare professionals, influencers and decision makers, patients and their families and those with an interest in urology health – to raise awareness of urological cancers and conditions.

This year’s theme was ‘ Men’s Urology Health: Myths and Legends’ . We addressed common myths around men’s urology health and encouraged men to ‘be a legend’ and open up about their own urology health. From prostate cancer and other urology cancers to bladder issues, erectile dysfunction and kidney stones, we spent the month urging males to recognise when something’s “not right below the belt” and speak out to get help. We created a range of resources to encourage good urology health including posters, infographics and informative leaflets.

18

The Urology Foundation Annual Report & Accounts 2024

As part of the campaign, we commissioned a survey via OnePoll exploring general awareness and perceptions of over 2000 men in the UK about urology health. Highlights from the survey include:

We also ran our own survey inviting UK nurses to give their views on men’s urology health and the barriers nurses face in supporting men. Highlights from the survey include:

The outcomes of the surveys provided an excellent platform to secure national coverage and promote a better understanding of the issues. Our thanks to Coloplast for supporting the survey and Infographics.

Other activities during Urology Awareness Month included:

19

The Urology Foundation Annual Report & Accounts 2024

We are grateful to everyone who supported UAM.

Movember

We were delighted to support Movember’s men’s health campaign and their new report, ‘ The Real Face of Men’s Health ’. The report examines how men engage with the health system and the full consequences of poor health on men, those immediately around men and those within their broader communities. It sets out recommendations that decision makers can take to improve men’s health outcomes, save costs within the NHS, and tackle the health inequalities that exist between different men. The report generated incredible support and coverage - from the media to policy makers, from patients to the global Movember community.

National Policy Activities

TUF has actively engaged in national policy conversations and inputted into national consultations that impact urology care throughout 2024. Highlights include:

UROLOGY PLEDGES 2024

In June we launched our Urology Pledges ‘ Excellent Urology Health for All ’ to influence health policy and increase awareness of the needs of the urology field to the next generation of parliamentarians and the new government. This provided the Foundation with valuable collateral with which to engage policy makers, proposing solutions and urging prospective parliamentary candidates and then the newly elected MPs to adopt them. The pledges were:

  1. Commit to investing in vital urology research

  2. Commit to investing in our urology community

  3. Commit to putting patients at the heart of decisions on urology care

Pre-election, we successfully launched the pledges at Cancer52’s Big Conversation event in Canary Wharf, London where we discussed the pledges and key issues with advisors at the Department of Health and Social Care who were tasked with developing briefings for the incoming government on cancer policy. The document was then shared widely on social media before being discussed with the community at the BAUS Annual Conference and shared via the BAUS Weekly Newsletter. Copies of the pledges were sent to key health spokespeople in each of the main parties including the Secretary of State for Health, Wes Streeting.

20

The Urology Foundation Annual Report & Accounts 2024

IN THE MEDIA

One in two of us will be affected by a urological cancer or condition yet these still do not attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and to ensure better outcomes and a quality of life alongside raising awareness of TUF and its vital work. Throughout the year we provided media spokespeople and commented on topical issues. Highlights included an interview on LBC on the subject of UTIs, as well as coverage in national press including The Telegraph, The Sunday Telegraph, Mail Online and The Mirror.

LAUNCH OF THE NEW WEBSITE

Our new website launched in May and has been extremely well received. With its distinct and contemporary look, the new website reflects our breadth of activities, our wider engagement and the impact we are making. It is a platform to connect with our urology community and for those with an interest in urology including the clinical and scientific community, patients and their families, decision makers and influencers, media, charity partners, and our supporters. Alongside celebrating our achievements, offering opportunities to get involved and showcasing patient experience, the site features our UTI Information Hub and information resources for patients and their families. Sincere thanks to The Champniss Foundation and The Champniss Charitable Trust for their generous support of the new website.

COLLABORATIONS AND PARTNERSHIPS

We value the importance of working with other organisations to achieve our aims. Throughout the year we engaged with a range of organisations and charity partners working in the area of urology. These included the BAUS, BAUN, Urology Trade Association, Prostate Cancer UK, Prostate Cancer Research, Fight Bladder Cancer, Action Bladder Cancer, Kidney Cancer UK and UCare.

TUF CEO was appointed as Vice Chair of Cancer52. Cancer52 is an organisation that represents over 100 charities and patient organisations focused on rare and less common cancers.

We were delighted to become a member of One Cancer Voice. One Cancer Voice is a coalition of over 60 cancer charities that advocate for better cancer care and outcomes in England and is coordinated by Cancer Research UK.

We welcomed the opportunity to meet and work with a range of companies including Medac Pharma, Johnson & Johnson, Androlab, Peppy Health, Intuitive Health, Boston Scientific, Pfizer UK, Peak Medical Ltd, Astellas Pharma, Bayer, Lloyds Pharmacy Online Doctor, Coloplast and Convatec to promote awareness of urology health.

CREATING STRONG FOUNDATIONS: INVESTING IN OUR TEAM

Developing our people and infrastructure is vital as it underpins the delivery of our charitable activities. The Trustees committed to infrastructure investment to support sustainability, effectiveness, collaboration and impact, particularly within the charity’s programmes and grants portfolio which has expanded significantly over the last three years, across fundraising and the expansion of funding streams and to ensure we have a “voice” within the urology community - in driving change, improving outcomes and patient care. The first stage of the investment saw the appointment of Laura Thorne as the new Director of Communications and Policy in 2023.

The second stage of the investment saw the following appointments in 2024:

21

The Urology Foundation Annual Report & Accounts 2024

PLANS FOR THE FUTURE

In 2025 we will continue to build on our work and achievements alongside:

22

The Urology Foundation Annual Report & Accounts 2024

FINANCIAL REVIEW

FINANCIAL RESULTS OF ACTIVITIES & EVENTS

----- Start of picture text -----
Financial Results: Income and Assets
4000000
3500000
3000000
2500000
2000000
1500000
1000000
500000
0
Net Assets Voluntary Income Event Income
2024 2023
----- End of picture text -----

The total value of net assets held by The Urology Foundation on 31 December 2024 was £3,762,840 (2023 £3,111,987). The Foundation’s fundraising activities and other initiatives during the course of 2024 generated a total of £2,018,269 of voluntary income (2023 £1,384,437) and a further £50,874 (2023 £66,800) from specific fundraising event income.

FUNDRAISING

The Foundation is reliant on voluntary income to fulfil its remit. Following a review of the charity’s fundraising function in 2022, the decision was made to invest in this area in order diversify the existing income streams and to look to increase the charity’s income. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diversified, sustainable sources of income. We are pleased to report income for year totalled £2,090,290 against the previous year total of £1,470,272. The following information summarises the various disciplines:

23

The Urology Foundation Annual Report & Accounts 2024

its impact on quality of life. Coloplast continued their support for UAM initiatives. Medac Pharma and Johnson & Johnson provided generous grants to fund two new bladder cancer projects which we will be delivering in 2025. Boston Scientific kindly supported the annual Bike4TUF. Looking ahead to 2025, we aim to further develop existing relationships while also exploring new partnerships to expand our reach and deliver even more impactful projects. We are deeply grateful to our many corporate partners for their continued support and generosity. Their contribution plays a vital role in enabling our work to improve the lives of those affected by urological cancers and conditions.

We are registered with the Fundraising Regulator and adhere to the code of fundraising when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising (IoF) and other professional bodies. The Foundation operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received less than five complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

RESERVES & LIQUIDITY POLICY

The Foundation currently total funds of £3,762,840 of which £1,813,138 are held as restricted funds, £2,921 are held as tangible fixed assets and £1,550,000 are held as designated funds (£500,000 minimum required reserves, £800,000 for research and £250,000 for infrastructure – see details below). Therefore, the Foundation has ‘free reserves’ of £396,781 (31 December 2023: £2,213,621).

24

The Urology Foundation Annual Report & Accounts 2024

The Foundation’s policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that the charity operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and investments to meet its liabilities and remain a going concern for at least 1 year in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as unrestricted funds. The Policy establishes a minimum liquidity target of £500,000 (“Minimum Required Reserve”) subject to future modification by the Finance Committee and Trustees’ approval.

The Trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of £500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects. The Trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

DESIGNATED FUNDS

In September 2024 the Board of Trustees approved designated funds for the following purpose:

Research Strategy 2024-2028
and Research Appeal		 A dedicated fund to support the new Research Strategy 2024-
2028 and associated Research Appeal. The strategy is an
exciting and ambitious plan to improve urology health and
transform lives through research over the next five years. It
builds on our history of clinical and academic innovation that
has already helped to revolutionise urology care. Trustees
have agreed to designate £1.5 million to enable the charity
to achieve its long-term vision and mission. £800,000 of this
is funded from designated unrestricted funds and £700,000
from a restricted legacydonation for scholarships.
Infrastructure A dedicated fund of £250k to invest in the development of
the charity’s infrastructure including patient experience,
campaigning, marketing, communications and to advance
our fundraising capabilities to further diversify income and
secure long-term sustainability.

STATEMENT OF GOING CONCERN

The Foundation’s unrestricted net funds generated in 2024 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

INVESTMENTS POLICY

The Foundation’s investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the Board of Trustees. The investment manager is asked to attend at least one Board of Trustees and one Finance Committee meeting annually.

The Board follows a medium risk ‘Balanced’ investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long-term horizon is the primary objective and some volatility is acceptable in order to achieve this. The charity’s investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 7.2% return over 2024.

25

The Urology Foundation Annual Report & Accounts 2024

All other Foundation funds are held in accounts with the charity’s bankers, National Westminster Bank plc.

REMUNERATION POLICY

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation’s guidance that a charity’s pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity’s aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

PENSIONS POLICY

The charity offers a stakeholder pension, operated by The People’s Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

EQUAL OPPORTUNITIES AND DIVERSITY POLICY

The charity is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or Trustee receives less favourable treatment on the grounds of their age, disability, gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. The charity also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.

The policy also applies to third parties such as Trustees and committee volunteers, clients (i.e. grant applicants) and suppliers.

PRINCIPAL RISKS AND UNCERTAINTIES

The Trustees take the management of risks seriously. The Chair of the Board of Trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept, updated and discussed by the Finance Committee and Board of Trustees on a quarterly basis.

Impact of war in Ukraine and economic outlook

The ongoing war in Ukraine and wider economic outlook have broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

Risks to Data

The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated Trustee (Mr Mark Becker) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and

26

The Urology Foundation Annual Report & Accounts 2024

delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance
/Environmental		 Impact of the external environment on fundraising, in particular: public
confidence in charities; new fundraising regulations; Data Protection
Regulations.
Income Sources TUF is reliant upon voluntary income as an annual source of funding. It is the
role of the Trustees to manage risk exposure on fundraising activities and in
doing so to accept an appropriate level of risk in order to raise income from
a wide range of sources.
Risk of data
breach		 The charity uses a professional database provider that stores all information
in the Cloud and this is secured using a two-step password verification. The
charity’s own day to day working documents are also stored on a cloud-based
system. TUF staff are regularly made aware of possible phishing scams and to
be alert to any potential email or system data breaches.
Key Person risk The small staff base makes TUF heavily reliant on the Chief Executive and a
few key Trustees so the unexpected loss or departure of the Chief Executive
or certain Trustees is a risk. Successionplanning processes are inplace.
Investment Risk TUF’s success is directly related to the amount of resource it can devote to
its objectives, so the key risk identified by Trustees relates to the proper
management of its funds. Imprudent or unprofessional decisions could
majorly impact on the performance of those funds. In common with similar
charities, TUF employs professional fund managers, whose performance is
regularlyreviewed bythe Treasurer together with other Trustees.
Risk to Employees Employees are not subject to risks other than those likely to be associated
with routine office work. Apart from obtaining statutory Employers Liability
Insurance, TUF nonetheless treats the welfare of its staff as a priority. The
Chief Executive is the Nominated Safety Officer for the purposes of the Health
and Safety at Work Act. The premises are checked and maintained by the
landlord / managing agency to ensure appropriate mitigation of the risk of
fire. Employees are aware of the location of fire extinguishers. The charity
also has a number of policies in place covering Equal Opportunities, Lone
Working,Workingfrom Home and Safe GuardingVulnerable People.
Risk that research
fails
to
deliver
results		 Grants awarded are subject to rigorous review by the SEC and Reviewing
Committee. Grantees are expected to submit progress reports and these are
reviewed by the SEC and TUF. The charity maintains ongoing communication
withgrant holders.
Loss of Records To protect against the loss of records, and to increase data security, files are
stored in the cloud. The risk of any unsaved data being critical to TUF is
regarded as insignificant. Other similar risks are dealt with byinsurance.

27

The Urology Foundation Annual Report & Accounts 2024

STRUCTURE, GOVERNANCE & MANAGEMENT

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

CHARITY GOVERNANCE CODE

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the Trustees, who meet three times each year including an Annual General Meeting.

TRUSTEE RECRUITMENT, TRAINING AND INDUCTION

The Foundation seeks to achieve a balance of lay and medical Trustees. Appointed Trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity’s Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new Trustees are provided with an induction programme and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

Trustees contribute to every aspect of the charity: governance; fundraising; financial planning; management expertise and leadership. We are truly grateful for their service and to all our Trustees, who selflessly contribute their time, expertise and networks whenever they are called upon.

APPOINTMENT & ELECTION

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven Trustees.

Two of the Trustees are required to be representative Trustees, one nominated by The British Association of Urological Surgeons (BAUS) and one nominated by British Journal of Urology International (BJUI). All other Trustees, known as appointed Trustees, are appointed by unanimous written resolution of all the Trustees present and/or voting at a special meeting of Trustees called to take place immediately before or after an ordinary meeting of Trustees.

The representative Trustee nominated by BAUS is the President of BAUS and the appointment to the board is concurrent with their post at BAUS, which is for a period of two years.

The Executive Team

The Chief Executive is responsible for the day-to-day management of the charity.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the Board of Trustees. She and the appropriate staff members attend the meetings of the Board of Trustees and sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

28

The Urology Foundation Annual Report & Accounts 2024

Scientific and Education Committee (SEC)

The SEC is responsible for the development and assessment of The Foundation’s research, education and training programmes and the review and administration of The Foundation’s grant making policy. The Chairman of the SEC is also a member of the Board of Trustees, and reports back to the Board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives.

Research Review Panel

The Research Review Panel is responsible for assessing applications for our major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Review Panel is made up of clinical Trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity’s website. They provide their services as volunteers and we are enormously grateful to them.

Finance Committee

The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chair of the Board and the Chairman of the SEC, and two other Trustees and the Chief Executive. Any recommendations made by the Finance Committee are brought to the Board of Trustees for discussion and ratification. The Treasurer has oversight of the charity’s bank and investment accounts.

IT Oversight Committee

The IT Oversight Committee was formed in 2023 on the recommendation of the Board of Trustees. The purpose of the IT Oversight Committee is to advise the Board of Trustees on IT governance, IT implementation and other strategic IT-related issues including legal and regulatory compliance, investment in IT projects including telecommunications, risk and opportunities and to ensure these are managed through appropriate internal controls. The IT Oversight Committee consists of a minimum of three Trustees including the Chair, the Chief Executive, Director of Research and Senior Administrative Officer.

RELATIONSHIPS WITH RELATED PARTIES

The Urology Foundation continues to maintain close links with its two founding charities, BAUS and the BJUI, whose representatives are Trustees.

REPRESENTATION ON OTHER BODIES

The Urology Foundation is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for our peer review processes, as well as advocating for charity-funded research with government. The charity is a National Institute for Health Research (NIHR) noncommercial Partner. This means the studies that the Foundation funds may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network.

The charity is also a member of Cancer52, Charities Research Involvement Group, the National Council for Voluntary Organisations (NCVO), Charity Finance Group, One Cancer Voice and UNSEEN, a UK leading anti-slavery charity working with survivors, businesses, governments, police and NHS to end slavery.

29

The Urology Foundation Annual Report & Accounts 2024

REFERENCE AND ADMINISTRATIVE DETAILS

The registered charity name is “The Urology Foundation” (sometimes referred to as “TUF”), a charity and a company limited by guarantee.

Chief Executive

Ms Rebecca Porta

Trustees

Ms Mary Garthwaite (Chair) Ms Angela Daniel (Treasurer) Mr Mark Becker (Secretary) Prof Rakesh Heer Ms Hilary Baker (appt 21 March 2024) Mr Mo Belal (appt 21 March 2024) Mr Ben Challacombe Ms Jo Creswell (resigned 17 June 2024) Mr Mike Griggs Prof Alan McNeill Mr Roland Morley (resigned 21 March 2024) Mr Kieran O’Flynn Mr Ian Pearce (appt 17 July 2024) Ms Julia Taylor (appt 21 March 2024) Ms Hannah Warren

President

Prof Roger Kirby

Patrons

Mr Handel Evans Sir Ranulph Fiennes OBE Mrs Rosemary Macaire Ms Jane Macquitty MBE Mr Steven Norris

Ambassadors

Mr Alex Corbisiero Sir Stephen Fry Mrs Kate Holmes

Registered Office

1-2 St Andrew’s Hill London EC4V 5BY

Charity number 1128683 (England & Wales)

Company number

06817868

Auditors

Sumer Auditco Limited Hermes House, Fire Fly Avenue, Swindon, Wiltshire, SN2 2GA

Bankers

National Westminster Bank plc PO Box 2021 10 Marylebone High Street London W1A 1FH

Investment Manager

Rothschild Bank (CI) Limited St. Julian’s Court, St. Julian’s Avenue St. Peter Port Guernsey GY1 3UA

30

The Urology Foundation Annual Report & Accounts 2024

TRUSTEES’ & DIRECTORS’ RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS

The Trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the Trustees’ Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the Trustees and directors are required to:

The Trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

AUDITOR

Following a review of auditors, the charity’s Trustees appointed Sumer Auditco Limited to undertake the 2024 audit. Mr James Gare (FCA), of Sumer Auditco Limited has agreed to act as Auditor.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO THE AUDITOR

The Trustees and directors at the date of approval of this Trustees’ annual report confirm that so far as each of them is aware, there is no relevant information of which the charity’s auditor is unaware, and the Trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

Mary Garthwaite, Chair Date: 21/09/2025

31

The Urology Foundation Annual Report & Accounts 2024

Report of the Independent Auditors to the Members of The Urology Foundation (Registered Number:06817868)

Opinion

We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

32

The Urology Foundation Annual Report & Accounts 2024

Report of the Independent Auditors to the Members of The Urology Foundation (Registered Number:06817868)

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees. We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the charity and its grant making activity, we identified that the principal risks of non-compliance with laws and regulations related to health and safety, employment law, Companies Act 2006 and Charity Law, and we considered the extent to which non-compliance might have a material effect on the financial statements of the charity. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006 and the Charities Statement of Recommended Practice.

We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls) and determined that the principal risks were

33

The Urology Foundation Annual Report & Accounts 2024

Report of the Independent Auditors to the Members of The Urology Foundation (Registered Number:06817868)

related to revenue recognition, management override, occurrence of grants and completeness of grants payable, and the potential lack of segregation of duties. Audit procedures performed by the audit engagement team included:

There are inherent limitations in the audit procedures described above and the further removed noncompliance with laws and regulations is from the events and the transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

fo-

James Gare FCA DChA (Senior Statutory Auditor) for and on behalf of Sumer Auditco Limited Statutory Auditors Hermes House Fire Fly Avenue Swindon Wiltshire SN2 2GA

22/09/2025

Date: .............................................

34

The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION LIR0￿y FWNDATICI STATEMENT OF FIFWKIAL AcnwTIES Lknre5trfcted Furbjs Totsl 2Q4 Fur 2Q3 INCOME Donation5 and Le8acie5 Other tradinq act1vit1es Investments IDTAL INCCWE 316,232 50.874 1,702,037 2,018,269 50.874 1,384,437 66.8C 388,253 1,702,037 2,090,290 1,470,2n EXPENDMJRE Rllslnq Funds Donations and Legacie5 Tradlne actI￿tIeS Investment mana£ement tosts 41.B43 46,201 2.039 43.882 48,210 35.852 37.315 78 ExFenthture on Charftabie thtle5 Ra15ine Awarene5S Grant makin8 167,654 548.Z18 8,038 789.958 175,692 1,338.176 137,135 1,078.079 1 288 459 166,315 166.523 1289,8331 1249.3481 .201 6YJ.853 471.646 114,5711 14,571 IZ63.9191 914.7T2 6YJ,853 471.646 at 1 2024 2.213,621 898.366 3.111.987 2.640.341 1 949 702 1 813 138 3 111 967 No separnte 5tatwiEDt ¢f trtal c147nyesin equity has been yesented as au >xh gairts a￿￿ lasses haye bew Lalt in ￿ sutement of finartial actr11￿5. 35 The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION THE UROLOGY FOUNDATION STATEMEKf OF FINANCIAL ACTivrriES for the year ended 31 December 2023 {Full fund comparatlve) FLmd5 2023 INCC Donotions and legacies Other tfadinq activitie5 Investments 140.195 66,800 19,035 1,244,242 1,384.437 66,800 19,035 1 470 272 TOTAL INCOIOE I Z44 Z42 EXPENDMJRE Ralslng Funds Donatlons and ie8aci•5 Trading aCti￿tTe5 Investment manaiement C05t5 Z4,761 21,357 11,091 15,959 35,85Z 37.315 laisini Awarene55 Grant making 82.382 198,193 54,753 879,886 137,135 1,078,079 1 288 459 11 289,471 362 289,833 188,730 Z82.915 471,646 Trar￿ter bet￿eTh 159,7061 129.024 342.621 471.646 Fu￿fj baLa￿e$ t¥OU8ht fcKward at l JaThJary ZOZ3 2.W.S?7 555.744 2.640,341 2 213 621 31117 ND Separate statem@nt of totsl changÈs in oquity has been pres￿t@d as aLI xh gairLS 1055 have d@alt with in thè s￿￿Me￿ of fina￿￿￿1 actiYitbPS. 36 The Urology Foundation Annual Report & Accounts 2024

19 September

21/09/2025

~~7.~~ Angela Daniel (Sep 22, 2025 11:54:22 GMT+1) ~~>~~ cece: Angela Daniel 22/09/2025

37

The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION IQ24 14 162 921 "vide￿ts and Intere51 from inve5tinerts manag￿ent I￿3 paid ftom investsints Pwcha5e of equpmEnt TrarGfer from G45h 17,394 14,019 11.8561 319,643 1317,0361 551,126 {307.833} Charye in cath and cath ewiyalerts in ￿p￿tIr￿ pwic Cash eq￿valents at tr bEsiMing of tr* repurtiry period Cash cash £q￿valefits at th2 end of the reporting period (2￿,287> ,477 38 The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2024

ACCOUNTING POLICIES

STATUTORY INFORMATION

The Urology foundation is a company limited by guarantee, without share capital, registered in England and Wales. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The charity's registration number is 1128683, registered company number is 06817868 and registered office address is 1-2 St Andrew’s Hill, London EC4V 5BY.

BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102. The financial statements are prepared in sterling which is the functional currency of the charity and rounded to the nearest pound. There are no significant areas of judgements or key sources of estimation uncertainty.

GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2024. As we prepare this statement in 2025, it is clear that the long tail of the COVID-19 pandemic, and its impact on the NHS workload, continues to have a bearing on the charity’s operations, with applications for programmes such as fellowships and travel grants still low. It remains to be seen whether our events fundraising and income will be impacted by global issues such as the war in Ukraine and the current cost of living crisis, which may affect future budgets for research and training. The trustees believe, however, that given the level of available cash and reserves, the charity can continue as a going concern.

INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accrual basis. Deferred income represents revenues collected but not earned as of 31 December 2024. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long-term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

39

The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2024

ACCOUNTING POLICIES

TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment

25% reducing balance

OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight-line basis over the lease term.

INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.

Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year-end are carried forward in the balance sheet.

DEFINED BENEFIT PENSION SCHEME

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

DEBTORS

Trade debtors, other debtors and accrued income are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

CREDITORS

Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors are normally recognised at their settlement amount after allowing for any trade discounts due.

CASH AT BANK AND IN HAND

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

TAXATION

The charity is exempt from corporation tax on its charitable activities.

40

The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2024

ACCOUNTING POLICIES

FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

41

The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION 99,494 186.971 29.767 1,C¥)4,752 1.104,246 186.971 n7,052 ,238.227 136.210 10,1)JO 697,285 1 70Z 037 2018 Z69 from tundraisir4 e%wts 74 Bank Interest receivable on short term cash deposlts Income from investments listed on recognlsed Stock exchange.. UK investments Overseas Investments 3,753 3,753 4.996 17,394 17,394 14.039 C05rs OF R4JSING FUNDS VCUNfAKf INC rect costs SuppDrt Costs 15ee note 81 5,931 35,912 30 2,009 5,961 37,921 5,812 30,040 42 The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION THE UROLOGY FOUNDATION NOTES TO THE FINANCIAL STAT&4IENTS for the year ended 31 December 2024 Unrestrlcted funds Restdcted funds 2024 2023 COSTS OF RAISING FUNDS TRADING ACTiwnES Costs of fundraising events Support costs (see note 81 10,289 35,912 10.289 37,921 7.276 30,040 2,(M)9 COSTS OF RAISING AWARENESS Cost5 of fundraising events Suprx)rt costs (see note 81 24,(KJ7 143,647 24.￿7 151,685 16,976 120,159 8,038 175 692 137 135 fund5 fur 2Q24 InThyatkn & Rese¥th Awards TUF TrlaL% Unlt nlss FUNI Da￿dT￿ATr Felity4shl Small Research Pro Ed￿atkn 8ur5arle5 a￿j GMIts Prke5 and award5 UN[￿￿ Nw )t¢)tk Centres ￿TrdInfj Oihw (Mrect costs Tr3vel Grants stra FurKY( Ur(dlnk Fellth*shl r5t elth Yea¢es medaL% awardEd to O WLJ: 1 I￿￿1￿1￿5 U5 10.570 516,939 527,5D9 435,592 110,0 43,5CO 110,( 43,5 120, 55.759 IOZ3'. 6 14.391 6,1(M> 272 lo.￿1 3,591 5,474 3,0 298 9.996 5,474 3,0 296 9.996 9.996 awarded to O 2013: 0 t Val￿ of ant accrua 24,918 955 576 104,511 278,089 Salary costs 5uprort t￿15 (see note 81 104,511 14,736 53,495 220,291 263,353 548,218 789,958 1,338,176 1,078,079 43 The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION THE UROLOGY FOUNDAMON NOTES TO THE FINANCLAL STATEMENTS for th• y•ar ended 31 December Z024 Costs of noratlng voluntary Incixne Fundraisl trathng.. Cast of ￿￿5 Awarene55 GI￿ni grants 55% 2024 2023 7.5% . SUPPORT AND fjOVERNANCE COSTS {UNREST￿CTEDj Staff costs (see rhf>te 91 l)ther staff c0513 including recruitment Cotnrnittee other Staff welfare expen5e5 Other offKe costs Audil fee Accountancy ar￿ ad￿SOry semces Other (￿t5 Depreciation-owned asset5 16,652 16.652 66,608 5.491 3.357 25,285 2.733 7,037 32.859 Z77 222.025 122,035 10,067 6.155 46,355 839 6,311 683 839 6,321 4.605 84.282 1,759 .215 69 12,902 (Q.241 Z3.458 109.528 924 13,738 47.267 8.215 69 143,647 263,353 478.823 260,40J 8. SUPPORT AND GOVERNANCE C05T5 {RESTWCTED} Slaff c05t5 Is£e nDle 91 Other staff costs Includlng recruiiment Committee and other staff welfare expenses Other office costs Audlt fee Accouniancy and adw50ry semces Other (<￿t5 DeprÈ¢1atl￿-oWne4 asseis 887 74 45 428 37 94 3.549 294 180 1.714 147 377 1,762 6.507 54D 330 3.142 269 692 3,230 27 74 45 428 37 94 440 3,896 1,504 73.742 600 1,258 5,872 50 4,486 15,435 167 44 The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION THE UROLLKY FCIJNDAmLV4 ¥)TES TO THE ￿NA￿lL ￿ATEmE￿r5 forthe year trkjed 31 t¢•nber Z024 2024 21r23 STAFF COSTS The averay monthly number of person5 employed by the ch•rity lexcludine trustee51 during the period was, as follows.. Offlce and admlnlstration Staff cesrs for the abjve Fersons.. Wales and salaries Social security c05ts Employer's Contrlbutlon to Deflned contrlbutlon Pen51on scheme 304,724 28,158 5,484 17,330 2,891 338 366 215 382 One ernployee received total emoluments in excess of E60,000 per annum durin2 the period ended 31 Decernber 2024 12023.. 11. The total emolument5 of these ernployees duriry the year were in the following ranqe5= Key manaeement personnel The remuneration of the key management personnel lincludinf ¢r05s pay, employer5. national insurarKe and employers pens1on contrfbutlonsl was E104.051 IZ023'. C101,6541. 2Q4 C90,OCbJ. £100.ri)) No. The Charfty ¢onsider5 Its key mJna8ement personnel comprise the Chief Executive, with remunerjtion as not¢d Jbove. In 5ettTn8 salary leve￿, The Urology Foundation follow5 the National Council for Voluntary Oriani5ation'5 ad￿ce that a charity 5 pay pollcy should be ¢0 offer falr pay to attract and keep approprfateiy-quallfied 5tdff to lead, manage, support andlor deliver the charity'5 aims. It also conducts online research of charity salari￿ and uses survey5 to benchmark levels of pay. The Urology Foundatlon dc¢s not au¢omat1cally award It$ staff with annual salary Increases, either incremental or c05t of li￿n8. No Director received any remuneration from the Company dunn8 the year 12023.. £nill. No trustee recelved any remuneratlon for semces protrfjded to the chaNty durfn2 the cutTent or prevlous perfod. Tru5tee5 expenses are included in note 20. TANGIBLE A5SErs Offlce Equlpment Cosr.. 1 January 2024 Addition5 24,350 310ecember 2024 24,350 Depreciation.. 1 January 2024 Charye for year 20,455 974 31 De￿mber 2024 Net bcok Yalue- 31 December 2024 31 December 2023 45 The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION THE UROLOGY FOUNDATION NOTE5 TO THE FINANCIAL STATEAIENTS for the year ended 31 December 2024 2024 2023 INVESTMENTS Ilsted on o recolnlsed swck exchange at market value.. 1 J¥thry 2024 Transfers from cash 3,453,644 3,407,104 337.038 1319,643 307.833 sposal rKoceeds Unreallsed (loss￿lI8a1TrS 166.523 289.830 31 December 2024 3.637.562 3.453.644 At th2 balance Sheet date, th2 market value of the mfolio £ompri5ed.. UK Investments 3,637,562 3,453,644 3,637,562 3,453,644 Flxed Incone secJrltles Iti-A&set & Hybr￿ Instruments 323.544 3,314,018 306.382 3,147,162 3 637 562 3 453 644 At rhe baiantr sheet date. htsrorlcal cos¢ of the Investmenrs was El,718,286 12023.. E2,7fQ,8921. The following holding5 had a value of .5% of the market value of the Investments.. Value £ 1014 3.314,018 Value t 1013 3.147,262 Nam Rothschild & Co WM SICAV-SIF Ex￿ry Fund GBP Pentalrs QIAIF PLC- Vanda Fund Shs-F- USD Shs Instiiuiionalcash SenesPLC- BlackRttk ICS Sterling LIqu￿ltY Fu Holdlng 123,544 306,181 12. 2024 Amounts falling due wthin one year.. Prepayments Acerued Income 17,348 1,209,061 1,ZZ6,409 18,978 421,203 440,181 46 The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION 11n￿nts fallins wrthin ￿r. 959 IXJ.239 11,939 611.010 13,382 Twade C￿ditC￿5 G￿er￿1 accruals Gr￿t xcrLoLs 7.183 795.zn Delred blfwd at 1 jar0￿￿ 2024 13,382 113,3821 Defeffed irKome clf¥4 at 31 Decembpr2024 falling in thaft0￿ yw. Grwrt 526.756 234.479 14. 6YJ.853 471.646 Ad]￿Thts for. 974 1166,5231 117,3941 Gain5 on inYest￿Dts Q89.8331 114.0391 Ilncrea5eil(*rea5e in dEbtcrfs I￿reaSe0{0Xrea5etr in ￿￿titorS (786.2291 118,033 Q6,7321 I￿.721> 28 47 The Urology Foundation Annual Report & Accounts 2024

THE UROLOGY FOUNDATION THE UROLOGY FOUNDATION FffiES TO THE nNANCIAL STATEMENTS for the year ended 31 December 2024 2024 lknlqr Trainiry F￿ld 106,418 2￿.14> 344.862 7.313 13.Q)Z 1Z6.556 85.197 112,XXJI 16 37 83, 197,616 416,595 7.314 9,461 21Z,OB6 137.475 44,%2 170.968 125,3451 Tèam Corbs. T*￿]clI Charles Rey￿id5 TIwy5aTr Farn11￿ Chants￿eTn I￿￿￿vati(￿ & Re5èarth thNards 13,5131 r214.5101 1343.8411 110,7461 3X.093 41,671 26 14,571 Events 6.839 898.366 14,571 1,7W2,037 )2,0151 Gen￿[al Designated IBIFI Rp5•arch Strategy 202¢28 & Ipwl 1.713.621 11,064,571> IB8.252 (803,9151 399,702 Infra3tnKtLre 3 111 987 1 605 959 Small Research Projects The transfer from General Funds to Srnall Research Projects Is to cover expenditure not externally funded in 2024. DEs￿NATED FUNDS Inse ember 2024 the Board of Trjstees a roved desl nated funds for the folLowfn ur Rese4r¢h Strategy 2024-ZOZ8 and A dedlcated fund to support the new Research Strateiy 2024-2028 and assoclated Rèsearch Nppeal Research Appeal. The Strategy 15 an exciting and ambitlOU5 plan to improve urol¢ey health and transform lives through research over the next five year5. It build5 on our history of clinical and academic innovathon that ha5 already helped to revolutsonise uroloey care. Thstees have aqreed to desi8nate £1.5 million to enable chanty to achleye Its lonf-term vlsion and mlsslon E81K).￿o of thls Is funded from desl8nated unrestrtct￿ funds and t700.{K￿ frorn a restrt¢ted legacy donat1on for seholarshlps. Infrastructure A dedicated fund of £250k to Invest in the development of the charity'5 infrastructure includinR patient expenence, campaiRnin£, marketing, communications and to advance our fundralsln8 capabllities to further dlverslfy Income and secure lon8-terni SUStsSnablllty. 48 The Urology Foundation Annual Report & Accounts 2024

15. THE FUNDS OF THE CHARITY (Continued)

THE FUNDS OF THE CHARITY (Full Fund Comparative)

49

The Urology Foundation Annual Report & Accounts 2024

The Urology Foundation

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2024

15. THE FUNDS OF THE CHARITY (Continued)

●Innovation & Research Awards. These are our key research awards, worth up to £60,000 per project to fund research and further our understanding into urological cancers and conditions.

●Small Research projects. These awards are primarily about studies that might improve patient pathways or treatment and care. Projects are worth £10,000 each.

●Campaigns – As part of the NHSE Cancer Programme’s abdominal/urological “Help Us, Help You” symptoms awareness campaign and specifically the symptom “Blood in Pee”, a series of community-based events were delivered across London. Visitors worried about a “blood in pee” symptom were encouraged to visit their GP or seek an early intervention.

●Events – The Foundation was pleased to receive support towards the TUF Trek to Namibia.

50

The Urology Foundation Annual Report & Accounts 2024